109 related articles for article (PubMed ID: 22108824)
1. Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1.
McBryan J; Theissen SM; Byrne C; Hughes E; Cocchiglia S; Sande S; O'Hara J; Tibbitts P; Hill AD; Young LS
Cancer Res; 2012 Jan; 72(2):548-59. PubMed ID: 22108824
[TBL] [Abstract][Full Text] [Related]
2. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
3. Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss.
Hiscox S; Barrett-Lee P; Borley AC; Nicholson RI
Eur J Cancer; 2010 Aug; 46(12):2187-95. PubMed ID: 20471823
[TBL] [Abstract][Full Text] [Related]
4. Interaction of developmental transcription factor HOXC11 with steroid receptor coactivator SRC-1 mediates resistance to endocrine therapy in breast cancer [corrected].
McIlroy M; McCartan D; Early S; O Gaora P; Pennington S; Hill AD; Young LS
Cancer Res; 2010 Feb; 70(4):1585-94. PubMed ID: 20145129
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor-β activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy.
Nair HB; Kirma NB; Ganapathy M; Vadlamudi RK; Tekmal RR
Steroids; 2011 Jul; 76(8):792-6. PubMed ID: 21477609
[TBL] [Abstract][Full Text] [Related]
6. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM
Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282
[TBL] [Abstract][Full Text] [Related]
7. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
Osipo C; Gajdos C; Cheng D; Jordan VC
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
[TBL] [Abstract][Full Text] [Related]
8. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
Kaufmann M; Rody A
Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
[TBL] [Abstract][Full Text] [Related]
10. Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer.
van de Velde CJ; Verma S; van Nes JG; Masterman C; Pritchard KI
Cancer Treat Rev; 2010 Feb; 36(1):54-62. PubMed ID: 19944537
[TBL] [Abstract][Full Text] [Related]
11. Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue.
Haugan Moi LL; Hauglid Flågeng M; Gandini S; Guerrieri-Gonzaga A; Bonanni B; Lazzeroni M; Gjerde J; Lien EA; DeCensi A; Mellgren G
Clin Cancer Res; 2010 Apr; 16(7):2176-86. PubMed ID: 20332317
[TBL] [Abstract][Full Text] [Related]
12. Are aromatase inhibitors superior to antiestrogens?
Howell A; Buzdar A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):237-47. PubMed ID: 15860266
[TBL] [Abstract][Full Text] [Related]
13. Are all aromatase inhibitors the same? A review of the current evidence.
Jänicke F
Breast; 2004 Dec; 13 Suppl 1():S10-8. PubMed ID: 15585378
[TBL] [Abstract][Full Text] [Related]
14. Clinical use of aromatase inhibitors in the treatment of advanced breast cancer.
Trunet PF; Vreeland F; Royce C; Chaudri HA; Cooper J; Bhatnagar AS
J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):241-5. PubMed ID: 9365196
[TBL] [Abstract][Full Text] [Related]
15. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
[TBL] [Abstract][Full Text] [Related]
16. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Belosay A; Brodie AM; Njar VC
Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
[TBL] [Abstract][Full Text] [Related]
17. Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer.
Al-azawi D; Ilroy MM; Kelly G; Redmond AM; Bane FT; Cocchiglia S; Hill AD; Young LS
Oncogene; 2008 May; 27(21):3021-31. PubMed ID: 18059336
[TBL] [Abstract][Full Text] [Related]
18. Prosaposin activates the androgen receptor and potentiates resistance to endocrine treatment in breast cancer.
Ali A; Creevey L; Hao Y; McCartan D; O'Gaora P; Hill A; Young L; McIlroy M
Breast Cancer Res; 2015 Sep; 17(1):123. PubMed ID: 26341737
[TBL] [Abstract][Full Text] [Related]
19. Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
Itoh T; Karlsberg K; Kijima I; Yuan YC; Smith D; Ye J; Chen S
Mol Cancer Res; 2005 Apr; 3(4):203-18. PubMed ID: 15831674
[TBL] [Abstract][Full Text] [Related]
20. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]